Stratagene and Focus Pen Dx Alliance; Third Wave s IP Not Likely Infringed | GenomeWeb

In a wide-ranging deal that signals Stratagene's intent to advance its molecular diagnostics goals in light of a recently lost patent battle, the company has licensed its FullVelocity technology to Focus Diagnostics and will supply materials related to the SNP-detection method, the company said this week.

Stratagene will also manufacture diagnostics developed by Focus as part of the deal and supply the privately held company with reagents for homebrew tests that Focus will sell in its reference labs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.